TRPV1 and hyperlipidemia: Cumulative experimental evidence showed that expression and/or activity of TRPV1 is increased in metabolic syndromes, such as in atherosclerosis (Zhao et al., 2013; Zhao et al., 2016), obesity (Motter and Ahern, 2008; Marshall et al., 2013; Singh et al., 2020; Cocci et al., 2021), hyperlipidemia and NAFLD (Wu et al., 2021), indicating that TRPV1 is involved in the signaling pathway that favors fat accumulation.